Oncology: new model of home treatment for Herceptin
The Christie NHS Foundation Trust, which treats over 40,000 patients each year, is one of Europe’s leading cancer centres, and an international leader in cancer research.
Partnering with The Christie, Healthcare at Home designed a care model for early stage HER2-positive breast cancer patients offering IV treatment with trastuzumab (Herceptin) our of hospital and in a place of the patient’s choice and convenience.
This clinically safe home treatment and prescription management service is delivered by a local, specialist Healthcare at Home nurse team; and is carried out under the direction of the patient’s consultant and the Christie’s breast cancer team.
The Christie is able to manage workload demands more effectively, and relieve pressure on nursing and pharmacy resources as well as accommodation and support services, all of which are at a premium at the hospital.
And, most importantly, with fewer hospital trips, one-to-one home nursing and a personalised support programme, there are high levels of patient satisfaction.
Between 2006 to 2008, 426 early stage HER2-positive breast cancer patients were enrolled onto the out-of-hospital IV treatment programme and treated at home.
- 5,087 home visits were undertaken by the Healthcare at Home nursing team
- The vast majority of patients were happy to be treated at home by the HaH service
- Over 90% reported agreeing or strongly agreeing that treatment at home was less stressful than treatment in hospital.
- No clinical incidents were recorded by Healthcare at Home
As a clinician I have been extremely happy with the service provided to my patients by Healthcare at Home. They provide a professional, organised and trustworthy service to me and my colleagues and to our patients. I have no hesitation in recommending Healthcare at
Home to patients.
Dr Greg Wilson, Consultant Oncologist, The Christie